臨床婦人科産科71巻10号

2017年10月発行

今月の臨床 最新！　婦人科がん薬物療法─化学療法薬から分子標的薬・免疫療法薬まで 子宮体がん

子宮肉腫に対する化学療法

著者： 高野忠夫¹

所属機関： ¹東北大学病院臨床研究推進センター

ページ範囲：P.992 - P.1001

●単剤化学療法と併用化学療法の臨床試験では，中等度の有効性を示す結果が得られている．

●初回補助化学療法のオプションとしては，ドキソルビシン単剤療法およびゲムシタビンとドセタキセルの併用療法（DG療法）が奨められる．

●パゾパニブ，トラベクテジン，エリブリンは，LMS治療の新たなオプションになる可能性がある．

●今後，LMSの分子学的特徴が明らかになり，新たなターゲットに対する治療戦略が開発されることが期待される．

参考文献

1）National Comprehensive Cancer Network（NCCN）guidelines www.nccn.org（Version 2.2017-April.2017）

2）Bell SW, et al : Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18 : 535─558, 1994

3）Moinfar F, et al : Uterine sarcomas. Pathology 39 : 55─71, 2007

4）Chen L, et al : Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 27 : 326─332, 2008

5）O'Neill CJ, et al : Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50 : 851─858, 2007

6）Akhan SE, et al : The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 99 : 36─42, 2005

7）Hwang H, et al : Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma : something old and something new. J Clin Pathol 68 : 710─717, 2015（doi:10.1136/jclinpath-2015-202915. Epub 2015 May 19.）

8）Mittal K, et al : Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 132 : 402─423, 2008

9）Omura GA, et al : A randomized clinical trial of adjuvant adriamycin in uterine sarcomas : a Gynecologic Oncology Group Study. J Clin Oncol 3 : 1240─1245, 1985

10）van Nagell JR Jr, et al : Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer 57 : 1451─1454, 1986

11）Hempling RE, et al : Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin（adriamycin）, and dacarbazine（CYVADIC） chemotherapy for stage I uterine sarcoma. A prospective trial. Am J Clin Oncol 18 : 282─286, 1995

12）Hensley ML, et al : Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma : Results of a prospective study. Gynecol Oncol 112 : 563─567, 2009（doi:10.1016/j.ygyno.2008.11.027. Epub 2009 Jan 9.）

13）Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II study. Gynecol Oncol 109 : 323─328, 2008 （doi:10.1016/j.ygyno.2008.02.024. Epub 2008 Apr 18.）

14）Hensley ML, et al : Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma : results of a phase 2 trial（SARC 005）. Cancer 119 : 1555─1561, 2013（doi:10.1002/cncr.27942. Epub 2013 Jan 18.）

15）Ioffe YJ, et al : Hormone receptor expression in uterine sarcomas : prognostic and therapeutic roles. Gynecol Oncol 115 : 466─471, 2009 （doi:10.1016/j.ygyno.2009.08.014. Epub 2009 Sep 20.）

16）Muss HB, et al : Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide（a phase III trial of the Gynecologic Oncology Group）. Cancer 55 : 1648─1653, 1985

17）Omura GA, et al : A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 : 626─632, 1983

18）Thigpen JT, et al : Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas : a Gynecologic Oncology Group study. J Clin Oncol 9 : 1962─1966, 1991

19）Sutton G, et al : Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Am J Obstet Gynecol 166 : 556─559, 1992

20）Sutton G, et al : Phase II evaluation of liposomal doxorubicin（Doxil） in recurrent or advanced leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 96 : 749─752, 2005

21）Thigpen JT, et al : Phase II trial of etoposide in leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 63 : 120─122, 1996

22）Rose PG, et al : Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 70 : 267─271, 1998

23）Sutton G, et al : Phase II trial of paclitaxel in leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 74 : 346─349, 1999

24）Miller DS, et al : Phase II trial of topotecan in patients with advanced, persistent or recurrent uterine leiomyosarcomas : a Gynecologic Oncology Group study. Am J Clin Oncol 23 : 355─357, 2000

25）Gallup DG, et al : Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 89 : 48─51, 2003

26）Look KY, et al : Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma : a Gynecologic Oncology Group（GOG） study. Gynecol Oncol 92 : 644─647, 2004

27）Monk BJ, et al : A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma : a gynecologic oncology group study. Gynecol Oncol 124 : 48─52, 2012（doi:10.1016/j.ygyno.2011.09.019. Epub 2011 Oct 13.）

28）Amant F, et al : Clinical outcome of ET-743（Trabectedin ; Yondelis） in high grade uterine sarcomas. Int J Gynecol Cancer 19 : 245─248, 2009

29）Kawai A, et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406─416, 2015（doi:10.1016/S1470─2045（15）70098─7. Epub 2015 Mar 18.）

30）Smith HO, et al : Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus : a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 84 : 140─144, 2002

31）Hensley ML, et al : Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma : A Gynecologic Oncology Group phase II study. Gynecol Oncol 98 : 99─103, 2005

32）Anderson S, et al : Temozolomide in uterine leiomyosarcomas. Gynecologic Oncology 98 : 99─103, 2005

33）McMeekin DS, et al : A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers : a Gynecologic Oncology Group study. Gynecol Oncol 105 : 508─516, 2007

34）van der Graaf WT, et al : EORTC Soft Tissue and Bone Sarcoma Group ; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma（PALETTE） : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879─1886, 2012（doi:10.1016/S0140-6736（12）60651-5. Epub 2012 May 16.）

35）Patrick Schöffski, et al : Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients（pts） with leiomyosarcoma（LMS） and adipocytic sarcoma（ADI）. J Clin Oncol 33, 2015（suppl ; abstr LBA10502）

36）Hannigan EV, et al : Treatment of advanced uterine sarcoma with vincristine, actinomycin D and cyclophosphamide. Gynecol Oncol 15 : 224─229, 1983

37）Sutton G, et al : Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 62 : 226─229, 1996

38）Edmonson JH, et al : Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma : a Gynecologic Oncology Group study. Gynecol Oncol 85 : 507─510, 2002

39）Hensley ML, et al : Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial. J Clin Oncol 12 : 2824─2831, 2002

40）Long HJ, et al : Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma : A Gynecologic Oncology Group study. Gynecol Oncol 99 : 339─342, 2005

41）Leyvraz S, et al : Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 17 : 646─651, 2006

42）Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109 : 324─329, 2008

43）Pautier P, et al : French Sarcoma Group. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma（LMS-02） : a non-randomised, multicentre, phase 2 trial. Lancet Oncol 16 : 457─464, 2015（doi:10.1016/S1470-2045（15）70070-7. Epub 2015 Mar 18.）

44）Hensley ML, et al : Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma : an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 33 : 1180─1185, 2015（doi:10.1200/JCO.2014.58.3781. Epub 2015 Feb 23）

45）Tap WD, et al : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial. Lancet 388 : 488─497, 2016